XBiotech Inc

4XB

Company Profile

  • Business description

    XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

  • Contact

    5217 Winnebago Lane
    AustinTX78744
    USA

    T: +1 512 386-2900

    E: [email protected]

    http://www.xbiotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    87

Stocks News & Analysis

stocks

ASX energy giant undervalued despite commissioning challenges

Near-term hurdles, long-term upside.
stocks

Undervalued ASX share upgrades guidance

Market share gains drive earnings upgrade despite a weak US housing backdrop.
stocks

ASX major bank drives strong quarterly profit

Profit momentum remains robust yet shares overvalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,112.0079.700.88%
CAC 408,428.0722.010.26%
DAX 4025,338.2122.82-0.09%
Dow JONES (US)52,531.97321.890.62%
FTSE 10010,850.1968.440.63%
HKSE25,310.85103.670.41%
NASDAQ24,602.99329.09-1.32%
Nikkei 22562,364.922,566.27-3.95%
NZX 50 Index13,861.9311.240.08%
S&P 5007,386.4926.69-0.36%
S&P/ASX 2008,947.8085.600.97%
SSE Composite Index3,813.3144.93-1.16%

Market Movers